In comparison with either general population or disease-modifying drugs-unexposed pregnancies, there was no raised link of unfavorable pregnancy outcomes in neonates with fetal exposure to disease-modifying drugs.

This cross-sectional study was carried out to explore pregnancy effects following early fetal exposure to injectable first-line therapies, Dimethyl fumarate, or Natalizumab in females having multiple sclerosis.

In this study, individual and composite adverse perinatal outcomes were assessed in pregnancies exposed to injectable first-line treatments (interferons or glatiramer acetate), Dimethyl fumarate, or Natalizumab compared with disease-modifying drugs (DMD)-unexposed pregnancies in females with multiple sclerosis  and pregnancies in the general population.

Data from Danish Multiple Sclerosis Registry was connected with national registries. After accounting for pertinent covariates, odds ratios with 95% confidence intervals for individual and composite unfavorable outcomes were estimated using logistic regression models accounting for clustered data.

A comparison was done between 91,112 pregnancies from the general population, 1009 DMD-exposed pregnancies, and 1073 DMD-unexposed pregnancies. When newborns with fetal exposure were compared to the general population, no increased risk of any perinatal outcome was discovered, incorporating any adverse event, placenta complication, stillbirth, low Apgar score, congenital malformation, spontaneous abortion, small for gestational age, and preterm birth. When comparing DMD-exposed and DMD-unexposed pregnancies, comparable outcomes were found.

The occurrence of stillbirths, spontaneous abortions, placenta problems, poor Apgar scores, small for gestational age, preterm delivery, and congenital malformations among newborns exposed to injectable first-line therapies, Dimethyl fumarate, or Natalizumab was comparable to that of the general population.